StockMacro
Menu

Compass Therapeutics

$0.69 -69% in 6 monthsMarket cap $123.9M

CMPX on XNAS, Health Care, Compass Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 86% in a year, a delisting notice arrived, and 23% of shares are sold short.

  • BadInstitutional holders fell 19%, from 211 filers to 170
  • BadNet loss of $86.4M over 12 months, with $163.1M cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
39
Website
compasstherapeutics.com
Listed
Nasdaq, US
Last results
9 Nov 2026
Next results
expected around 5 Jan 2027 (an estimate: a year ago it reported on 6 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $27.2M.
Quarter to 31 Dec 2021: revenue –, net income -$13.0MQuarter to 31 Mar 2022: revenue –, net income -$7.2MQuarter to 30 Jun 2022: revenue –, net income -$8.5MQuarter to 30 Sep 2022: revenue –, net income -$12.0MQuarter to 31 Dec 2022: revenue –, net income -$11.6MQuarter to 31 Mar 2023: revenue –, net income -$7.8MQuarter to 30 Jun 2023: revenue $0, net income -$11.3MQuarter to 30 Jun 2023: revenue $0, net income -$11.3MQuarter to 30 Sep 2023: revenue $0, net income -$10.0MQuarter to 30 Sep 2023: revenue $0, net income -$10.0MQuarter to 31 Dec 2023: revenue $0, net income -$13.4MQuarter to 31 Dec 2023: revenue $0, net income -$13.4MQuarter to 31 Mar 2024: revenue –, net income -$10.8MQuarter to 30 Jun 2024: revenue $850K, net income -$13.1MQuarter to 30 Jun 2024: revenue $850K, net income -$13.1MQuarter to 30 Sep 2024: revenue $0, net income -$10.5MQuarter to 30 Sep 2024: revenue $0, net income -$10.5MQuarter to 31 Dec 2024: revenue $0, net income -$15.0MQuarter to 31 Dec 2024: revenue $0, net income -$15.0MQuarter to 31 Mar 2025: revenue –, net income -$16.6MQuarter to 30 Jun 2025: revenue $0, net income -$19.9MQuarter to 30 Jun 2025: revenue $0, net income -$19.9MQuarter to 30 Sep 2025: revenue $0, net income -$14.3MQuarter to 30 Sep 2025: revenue $0, net income -$14.3MQuarter to 31 Dec 2025: revenue $0, net income -$15.7MQuarter to 31 Dec 2025: revenue $0, net income -$15.7MQuarter to 31 Mar 2026: revenue –, net income -$18.3MQuarter to 30 Jun 2026: revenue –, net income -$25.2MQuarter to 30 Sep 2026: revenue –, net income -$27.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $27.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$27.2M
30 Jun 2026–-$25.2M
31 Mar 2026–-$18.3M
31 Dec 2025$0-$15.7M
30 Sep 2025$0-$14.3M
30 Jun 2025$0-$19.9M
31 Mar 2025–-$16.6M
31 Dec 2024$0-$15.0M
30 Sep 2024$0-$10.5M
30 Jun 2024$850K-$13.1M
31 Mar 2024–-$10.8M
31 Dec 2023$0-$13.4M
30 Sep 2023$0-$10.0M
30 Jun 2023$0-$11.3M
31 Mar 2023–-$7.8M
31 Dec 2022–-$11.6M
30 Sep 2022–-$12.0M
30 Jun 2022–-$8.5M
31 Mar 2022–-$7.2M
31 Dec 2021–-$13.0M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$86.4M -$65.8M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -49.0% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $163.1M $219.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$163.1M (net cash) -$219.9M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.79
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.87 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Compass TherapeuticsCMPX (this company) $123.9Mloss–––
HumacyteHUMA $123.7Mloss51.6+53%–
InvivydIVVD $122.0Mloss2.0+21%-215%
enGene TherapeuticsENGN $116.6Mloss–––
Armata PharmaceuticalsARMP $112.7Mloss–––
Fate TherapeuticsFATE $111.8Mloss23.5-33%–

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$27K

bought $27K, sold $0

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-19%

170 13F filers vs 211

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

159.1M shares held by 13F filers (30 Sep 2026) of 180.1M outstanding (5 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

23%

40.8M shares sold short (30 Oct 2026) of 180.1M outstanding (5 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

18.9

40.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.5%

41.8M shares sold short in the report before, 40.8M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

39%

39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 45%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

18

18 articles in the last 7 days; its usual week has 6.5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

2.8×

18 articles in the last 7 days; its usual week has 6.5.

Price $0.69 on 20 Nov 2026, -86% over 12 months (12-month range $0.61 to $6.69)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $27K in the last 12 months (the 12 months before: -$5.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $106K in the latest quarter, +1414% on a year earlier.
Institutional holders (13F filers). 170 13F filers reported holding it in the latest 13F quarter, +43% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
20 Nov 20268-K and other filingsNasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 47 vs usual 12.50 (2025-12-31); 3.4x the same period a year earlier
18 Nov 2025Sharp changeMany funds opening a new position: many funds opening a new position, 27 vs usual 10.50 (2025-09-30); 2.7x the same period a year earlier
29 Jul 2025Sharp changeShort interest spike: short interest spike, 7.8M vs usual 2.6M (2025-07-15); 3.9x the same period a year earlier
1 Jul 2025Sharp changeShort interest spike: short interest spike, 7.4M vs usual 2.3M (2025-06-13); 4.7x the same period a year earlier
17 Jun 2025Sharp changeShort interest spike: short interest spike, 7.4M vs usual 2.2M (2025-05-30); 4.8x the same period a year earlier
3 Jun 2025Sharp changeShort interest spike: short interest spike, 6.9M vs usual 2.2M (2025-05-15); 4.2x the same period a year earlier
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 25 vs usual 10.50 (2025-03-31); 2.8x the same period a year earlier
13 May 2025Sharp changeShort interest spike: short interest spike, 7.6M vs usual 2.1M (2025-04-30); 4.6x the same period a year earlier
29 Apr 2025Sharp changeShort interest spike: short interest spike, 8.2M vs usual 2.0M (2025-04-15); 5.1x the same period a year earlier
15 Apr 2025Sharp changeShort interest spike: short interest spike, 6.6M vs usual 1.9M (2025-03-31); 4.1x the same period a year earlier
1 Apr 2025Sharp changeShort interest spike: short interest spike, 4.6M vs usual 1.9M (2025-03-14); 2.4x the same period a year earlier
18 Mar 2025Sharp changeShort interest spike: short interest spike, 3.7M vs usual 1.8M (2025-02-28); 2.0x the same period a year earlier
4 Mar 2025Sharp changeShort interest spike: short interest spike, 3.5M vs usual 1.8M (2025-02-14); 1.8x the same period a year earlier
28 Jan 2025Sharp changeShort interest spike: short interest spike, 3.2M vs usual 1.8M (2025-01-15); 1.6x the same period a year earlier
10 Dec 20248-K and other filingsDirector or officer change
10 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 May 20248-K and other filingsDirector or officer change
28 May 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Jan 20248-K and other filingsDirector or officer change
9 Jan 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Jul 2023Sharp changeShort interest spike: short interest spike, 4.3M vs usual 625K (2023-06-30); 40.6x the same period a year earlier
4 Jul 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 254K (2023-06-15); 26.4x the same period a year earlier
13 Jun 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 181K (2023-05-31); 13.0x the same period a year earlier
30 May 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 181K (2023-05-15); 8.9x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 162K (2023-04-28); 17.3x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 159K (2023-04-14); 12.8x the same period a year earlier
24 Apr 20238-K and other filingsDirector or officer change
18 Apr 2023Sharp changeShort interest spike: short interest spike, 2.0M vs usual 159K (2023-03-31); 2.7x the same period a year earlier
28 Mar 2023Sharp changeShort interest spike: short interest spike, 2.1M vs usual 159K (2023-03-15); 2.8x the same period a year earlier
14 Mar 2023Sharp changeShort interest spike: short interest spike, 1.8M vs usual 159K (2023-02-28); 5.6x the same period a year earlier
28 Feb 2023Sharp changeShort interest spike: short interest spike, 2.2M vs usual 159K (2023-02-15); 8.8x the same period a year earlier
24 Feb 20238-K and other filingsDirector or officer change
14 Feb 2023Sharp changeShort interest spike: short interest spike, 1.9M vs usual 159K (2023-01-31); 6.1x the same period a year earlier
10 Feb 20238-K and other filingsDirector or officer change
31 Jan 2023Sharp changeShort interest spike: short interest spike, 1.0M vs usual 159K (2023-01-13); 3.9x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 935K vs usual 153K (2022-12-30); 25.4x the same period a year earlier
29 Nov 20228-K and other filingsDirector or officer change
2 Nov 20228-K and other filingsDirector or officer change
19 Aug 20228-K and other filingsDirector or officer change
19 Aug 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Aug 20228-K and other filingsA major agreement ended
14 May 2022Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 668K)
26 Apr 20228-K and other filingsDirector or officer change
25 Feb 20228-K and other filingsDirector or officer change
21 Dec 20218-K and other filingsDirector or officer change
21 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 May 2022: $828K published
Month from 1 Jun 2022: $317K published
Month from 1 Aug 2022: $124K published
Month from 1 Sep 2022: $145K published
Month from 1 Nov 2022: $1.1M published
Month from 1 Jan 2023: $84K published
Month from 1 Feb 2023: $238K published
Month from 1 Mar 2023: $34K published
Month from 1 Apr 2025: -$5.6M published
Month from 1 May 2025: $21K published
Month from 1 Sep 2026: $3K published
Month from 1 Oct 2026: $18K published
Month from 1 Nov 2026: $6K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 30 Jun 2023: $0; public on 13 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 13 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2024: $850K; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $0; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $0; public on 28 Feb 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 6 Mar 2026
Capital spending per quarter
Quarter ended 20 Jun 2021: $296K; public on 2 Aug 2022
Quarter ended 31 Dec 2021: $777K; public on 19 Mar 2022
Quarter ended 31 Mar 2022: $194K, +52% on a year earlier; public on 10 May 2022
Quarter ended 30 Sep 2022: $27K, -93% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $54K, -93% on a year earlier; public on 16 Mar 2023
Quarter ended 31 Mar 2023: $0, -100% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $11K; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $10K, -63% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $9K, -83% on a year earlier; public on 22 Mar 2024
Quarter ended 31 Mar 2024: $0; public on 9 May 2025
Quarter ended 30 Jun 2024: $0, -100% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $44K, +340% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $18K; public on 9 May 2025
Quarter ended 30 Sep 2025: $7K, -84% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $82K, +356% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $176K; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $106K, +1414% on a year earlier; public on 10 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 35; public on 14 Feb 2022
31 Mar 2022 report: 33; public on 16 May 2022
30 Jun 2022 report: 32; public on 15 Aug 2022
30 Sep 2022 report: 36; public on 14 Nov 2022
31 Dec 2022 report: 52; public on 14 Feb 2023
31 Mar 2023 report: 69; public on 15 May 2023
30 Jun 2023 report: 69; public on 14 Aug 2023
30 Sep 2023 report: 73; public on 14 Nov 2023
31 Dec 2023 report: 70; public on 14 Feb 2024
31 Mar 2024 report: 75; public on 15 May 2024
30 Jun 2024 report: 77; public on 14 Aug 2024
30 Sep 2024 report: 77; public on 14 Nov 2024
31 Dec 2024 report: 91; public on 14 Feb 2025
31 Mar 2025 report: 105; public on 15 May 2025
30 Jun 2025 report: 99; public on 14 Aug 2025
30 Sep 2025 report: 119; public on 14 Nov 2025
31 Dec 2025 report: 164; public on 17 Feb 2026
31 Mar 2026 report: 195; public on 15 May 2026
30 Jun 2026 report: 211; public on 14 Aug 2026
30 Sep 2026 report: 170; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $22.0M (30 Sep 2026), 1.7× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $27K in the last 12 months (the 12 months before: -$5.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 1 published in the last 12 months (none in the 12 months before).
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 46 insider trades

Last 90 days: no sales; 3 purchases, $27K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
18 Nov 2026Neil LernerChief Accounting OfficerBuy10,000$0.59$6KForm 4
2 Oct 2026Neil LernerChief Accounting OfficerBuy20,000$0.92$18KForm 4
25 Sep 2026Neil LernerChief Accounting OfficerBuy2,500$1.14$3KForm 4
27 May 2025Thomas J. SchuetzCHIEF EXECUTIVE OFFICERBuy10,000$2.11$21KForm 4
11 Apr 2025OrbiMed Capital GP VI LLC and 2 othersDirector, 10% ownerSell3,571,428$1.59$5.7MForm 4
8 Apr 2025Jonathan AndermanGen Counsel & Corporate SecBuy20,000$1.54$31KForm 4
8 Apr 2025Neil LernerCHIEF ACCOUNTING OFFICERBuy20,000$1.42$28KForm 4
10 Mar 2023Thomas J. SchuetzCHIEF EXECUTIVE OFFICERBuy10,000$3.37$34KForm 4

170 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 19 opened a position, 55 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Tang Capital Management LLC18.0M9.99%$18.7MNo change
Orbimed Advisors LLC15.2M8.45%$15.8MNo change
Montanova Capital, LLC14.3M7.96%$14.9M+226K+1.6%
BlackRock, Inc.11.4M6.33%$11.9M+113K+1.0%
Enavate Sciences GP, LLC7.8M4.32%$8.1MNo change
State Street Corp7.7M4.30%$8.0M-2.2M-22%
Palo Alto Investors LP7.1M3.97%$7.4M+1.3M+23%
Vanguard Capital Management LLC6.0M3.33%$6.2M-124K-2.0%
Millennium Management LLC4.7M2.60%$4.9M-27K-0.6%
Qube Research & Technologies Ltd4.2M2.32%$4.3M+483K+13%

Company events

All 35 company events

In 12 months: 1 delisting notice. Results releases and routine reports are left out.

FiledWhat happenedSource
20 Nov 2026Nasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance8-K
13 Aug 2025Signed a major agreement8-K
10 Dec 2024Director or officer change8-K
28 May 2024Director or officer change8-K
9 Jan 2024Director or officer change8-K
24 Apr 2023Director or officer change8-K
24 Feb 2023Director or officer change8-K
10 Feb 2023Director or officer change8-K

The 5 newest of 237 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

15 May 2025confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Compass Therapeutics (CMPX): had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year. Two unrelated kinds of activity within 105 days.

  • Short interest and volume: Short interest spike, became public on 10 Apr 2025
  • Short interest and volume: Short interest spike, became public on 26 Apr 2025
  • Short interest and volume: Short interest spike, became public on 10 May 2025
  • Institutional holdings: Many funds opening a new position, became public on 15 May 2025
  • Short interest and volume: Short interest spike, became public on 28 May 2025
  • Short interest and volume: Short interest spike, became public on 11 Jun 2025
  • Short interest and volume: Short interest spike, became public on 26 Jun 2025
  • Short interest and volume: Short interest spike, became public on 25 Jul 2025
2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M
The 30 Apr 2025 report against the 24 reports before it. this reportearliernormal: 2.1M
See the evidence (8 changes)

Short interest and volume: Short interest spike became public on 10 Apr 2025

Compass Therapeutics had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.

This period
6.6M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
304K
How far from its usual level
+10.5
Same report last year
1.6M
History used
1,431 days
2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M
the 31 Mar 2025 report24 earlier reportsnormal: 1.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Apr 2025

Compass Therapeutics had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.

This period
8.2M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
343K
How far from its usual level
+12.2
Same report last year
1.6M
History used
1,446 days
2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M
the 15 Apr 2025 report24 earlier reportsnormal: 2.0M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 May 2025

Compass Therapeutics had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.

This period
7.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
427K
How far from its usual level
+8.8
Same report last year
1.6M
History used
1,461 days
2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M
the 30 Apr 2025 report24 earlier reportsnormal: 2.1M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 May 2025

Compass Therapeutics saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.

This period
25 (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+3.9
Same quarter last year
9
History used
1,186 days
2023-03-31: 222023-06-30: 252023-09-30: 72023-12-31: 112024-03-31: 92024-06-30: 92024-09-30: 102024-12-31: 142025-03-31: 25
the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 28 May 2025

Compass Therapeutics had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.

This period
6.9M (the 15 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
545K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,476 days
2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M
the 15 May 2025 report24 earlier reportsnormal: 2.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jun 2025

Compass Therapeutics had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.

This period
7.4M (the 30 May 2025 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
583K
How far from its usual level
+6.0
Same report last year
1.6M
History used
1,491 days
2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M
the 30 May 2025 report24 earlier reportsnormal: 2.2M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Jun 2025

Compass Therapeutics had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.

This period
7.4M (the 13 Jun 2025 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
583K
How far from its usual level
+5.9
Same report last year
1.6M
History used
1,505 days
2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M
the 13 Jun 2025 report24 earlier reportsnormal: 2.3M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Jul 2025

Compass Therapeutics had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.

This period
7.8M (the 15 Jul 2025 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
876K
How far from its usual level
+4.0
Same report last year
2.0M
History used
1,537 days
2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M2025-06-30: 7.4M2025-07-15: 7.8M
the 15 Jul 2025 report24 earlier reportsnormal: 2.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 20 Nov 2026Filings record

    Nasdaq notice: bid price below $1.00 for 30 consecutive business days; has until May 18, 2027 to regain compliance

  2. 18 Nov 2026Insiders record

    Lerner Neil (Chief Accounting Officer) bought 10,000 shares of CMPX ($5,900)

  3. 2 Oct 2026Insiders record

    Lerner Neil (Chief Accounting Officer) bought 20,000 shares of CMPX ($18,400)

  4. 26 Sep 2026Insiders record

    Lerner Neil (Chief Accounting Officer) bought 2,500 shares of CMPX ($2,850) (dated 25 Sep 2026)

  5. 1 May 2026Insiders record

    Lerner Neil (Chief Accounting Officer) bought 15,000 shares of CMPX ($28,350) [amended] (dated 30 Apr 2026)

  6. 1 May 2026Insiders record

    Anderman Jonathan (General Counsel) bought 25,000 shares of CMPX ($47,250) [amended] (dated 30 Apr 2026)

  7. 17 Feb 2026Institutional holdings change

    saw 47 13F filers open a new position in the quarter ended 31 Dec 2025, 3.4× the same quarter last year.

    Same quarter last year: 14; its normal quarter is 12.5.

    See the evidence
    This period
    47 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    12.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +6.6
    Same quarter last year
    14
    History used
    1,461 days
    2023-12-31: 112024-03-31: 92024-06-30: 92024-09-30: 102024-12-31: 142025-03-31: 252025-06-30: 192025-09-30: 272025-12-31: 47
    the quarter ended 31 Dec 20258 earlier quartersnormal: 12.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  8. 14 Nov 2025Institutional holdings change

    saw 27 13F filers open a new position in the quarter ended 30 Sep 2025, 2.7× the same quarter last year.

    Same quarter last year: 10; its normal quarter is 10.5.

    See the evidence
    This period
    27 (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +4.5
    Same quarter last year
    10
    History used
    1,369 days
    2023-09-30: 72023-12-31: 112024-03-31: 92024-06-30: 92024-09-30: 102024-12-31: 142025-03-31: 252025-06-30: 192025-09-30: 27
    the quarter ended 30 Sep 20258 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  9. 25 Jul 2025Short interest and volume change

    had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.

    Same report last year: 2.0M; its normal report is 2.6M.

    See the evidence
    This period
    7.8M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    876K
    How far from its usual level
    +4.0
    Same report last year
    2.0M
    History used
    1,537 days
    2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M2025-06-30: 7.4M2025-07-15: 7.8M
    the 15 Jul 2025 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 26 Jun 2025Short interest and volume change

    had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.

    Same report last year: 1.6M; its normal report is 2.3M.

    See the evidence
    This period
    7.4M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    583K
    How far from its usual level
    +5.9
    Same report last year
    1.6M
    History used
    1,505 days
    2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M
    the 13 Jun 2025 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 11 Jun 2025Short interest and volume change

    had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.

    Same report last year: 1.6M; its normal report is 2.2M.

    See the evidence
    This period
    7.4M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    583K
    How far from its usual level
    +6.0
    Same report last year
    1.6M
    History used
    1,491 days
    2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M
    the 30 May 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  12. 28 May 2025Short interest and volume change

    had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.

    Same report last year: 1.6M; its normal report is 2.2M.

    See the evidence
    This period
    6.9M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    545K
    How far from its usual level
    +5.9
    Same report last year
    1.6M
    History used
    1,476 days
    2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M
    the 15 May 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 28 May 2025Insiders record

    Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) bought 10,000 shares of CMPX ($21,100) (dated 27 May 2025)

  14. 15 May 2025several at once

    had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year, while it saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year. Two unrelated kinds of activity within 105 days.

    See the evidence (8 changes)

    Short interest and volume: Short interest spike became public on 10 Apr 2025

    Compass Therapeutics had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.

    This period
    6.6M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    304K
    How far from its usual level
    +10.5
    Same report last year
    1.6M
    History used
    1,431 days
    2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M
    the 31 Mar 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Apr 2025

    Compass Therapeutics had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.

    This period
    8.2M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    343K
    How far from its usual level
    +12.2
    Same report last year
    1.6M
    History used
    1,446 days
    2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M
    the 15 Apr 2025 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 May 2025

    Compass Therapeutics had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.

    This period
    7.6M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    427K
    How far from its usual level
    +8.8
    Same report last year
    1.6M
    History used
    1,461 days
    2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M
    the 30 Apr 2025 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 15 May 2025

    Compass Therapeutics saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.

    This period
    25 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +3.9
    Same quarter last year
    9
    History used
    1,186 days
    2023-03-31: 222023-06-30: 252023-09-30: 72023-12-31: 112024-03-31: 92024-06-30: 92024-09-30: 102024-12-31: 142025-03-31: 25
    the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 28 May 2025

    Compass Therapeutics had 6.9M shares sold short in the 15 May 2025 report, 4.2× the same report last year.

    This period
    6.9M (the 15 May 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    545K
    How far from its usual level
    +5.9
    Same report last year
    1.6M
    History used
    1,476 days
    2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M
    the 15 May 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jun 2025

    Compass Therapeutics had 7.4M shares sold short in the 30 May 2025 report, 4.8× the same report last year.

    This period
    7.4M (the 30 May 2025 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    583K
    How far from its usual level
    +6.0
    Same report last year
    1.6M
    History used
    1,491 days
    2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M
    the 30 May 2025 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 26 Jun 2025

    Compass Therapeutics had 7.4M shares sold short in the 13 Jun 2025 report, 4.7× the same report last year.

    This period
    7.4M (the 13 Jun 2025 report)
    Normal report (median of 24 earlier)
    2.3M
    Typical spread (median absolute deviation)
    583K
    How far from its usual level
    +5.9
    Same report last year
    1.6M
    History used
    1,505 days
    2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M
    the 13 Jun 2025 report24 earlier reportsnormal: 2.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Jul 2025

    Compass Therapeutics had 7.8M shares sold short in the 15 Jul 2025 report, 3.9× the same report last year.

    This period
    7.8M (the 15 Jul 2025 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    876K
    How far from its usual level
    +4.0
    Same report last year
    2.0M
    History used
    1,537 days
    2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M2025-05-15: 6.9M2025-05-30: 7.4M2025-06-13: 7.4M2025-06-30: 7.4M2025-07-15: 7.8M
    the 15 Jul 2025 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  15. 15 May 2025Institutional holdings change

    saw 25 13F filers open a new position in the quarter ended 31 Mar 2025, 2.8× the same quarter last year.

    Same quarter last year: 9; its normal quarter is 10.5.

    See the evidence
    This period
    25 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    10.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +3.9
    Same quarter last year
    9
    History used
    1,186 days
    2023-03-31: 222023-06-30: 252023-09-30: 72023-12-31: 112024-03-31: 92024-06-30: 92024-09-30: 102024-12-31: 142025-03-31: 25
    the quarter ended 31 Mar 20258 earlier quartersnormal: 10.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 10 May 2025Short interest and volume change

    had 7.6M shares sold short in the 30 Apr 2025 report, 4.6× the same report last year.

    Same report last year: 1.6M; its normal report is 2.1M.

    See the evidence
    This period
    7.6M (the 30 Apr 2025 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    427K
    How far from its usual level
    +8.8
    Same report last year
    1.6M
    History used
    1,461 days
    2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M2025-04-30: 7.6M
    the 30 Apr 2025 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  17. 26 Apr 2025Short interest and volume change

    had 8.2M shares sold short in the 15 Apr 2025 report, 5.1× the same report last year.

    Same report last year: 1.6M; its normal report is 2.0M.

    See the evidence
    This period
    8.2M (the 15 Apr 2025 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    343K
    How far from its usual level
    +12.2
    Same report last year
    1.6M
    History used
    1,446 days
    2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M2025-04-15: 8.2M
    the 15 Apr 2025 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  18. 10 Apr 2025Short interest and volume change

    had 6.6M shares sold short in the 31 Mar 2025 report, 4.1× the same report last year.

    Same report last year: 1.6M; its normal report is 1.9M.

    See the evidence
    This period
    6.6M (the 31 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    304K
    How far from its usual level
    +10.5
    Same report last year
    1.6M
    History used
    1,431 days
    2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M2025-03-31: 6.6M
    the 31 Mar 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  19. 9 Apr 2025Insiders record

    Anderman Jonathan (Gen Counsel & Corporate Sec) bought 20,000 shares of CMPX ($30,800) (dated 8 Apr 2025)

  20. 9 Apr 2025Insiders record

    Lerner Neil (CHIEF ACCOUNTING OFFICER) bought 20,000 shares of CMPX ($28,400) (dated 8 Apr 2025)

  21. 26 Mar 2025Short interest and volume change

    had 4.6M shares sold short in the 14 Mar 2025 report, 2.4× the same report last year.

    Same report last year: 1.9M; its normal report is 1.9M.

    See the evidence
    This period
    4.6M (the 14 Mar 2025 report)
    Normal report (median of 24 earlier)
    1.9M
    Typical spread (median absolute deviation)
    269K
    How far from its usual level
    +6.9
    Same report last year
    1.9M
    History used
    1,414 days
    2024-03-15: 1.9M2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M2025-03-14: 4.6M
    the 14 Mar 2025 report24 earlier reportsnormal: 1.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 12 Mar 2025Short interest and volume change

    had 3.7M shares sold short in the 28 Feb 2025 report, 2.0× the same report last year.

    Same report last year: 1.8M; its normal report is 1.8M.

    See the evidence
    This period
    3.7M (the 28 Feb 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    243K
    How far from its usual level
    +5.1
    Same report last year
    1.8M
    History used
    1,400 days
    2024-02-29: 1.8M2024-03-15: 1.9M2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M2025-02-28: 3.7M
    the 28 Feb 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 27 Feb 2025Short interest and volume change

    had 3.5M shares sold short in the 14 Feb 2025 report, 1.8× the same report last year.

    Same report last year: 2.0M; its normal report is 1.8M.

    See the evidence
    This period
    3.5M (the 14 Feb 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    228K
    How far from its usual level
    +5.0
    Same report last year
    2.0M
    History used
    1,386 days
    2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 1.9M2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M2025-01-31: 2.7M2025-02-14: 3.5M
    the 14 Feb 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 28 Jan 2025Short interest and volume change

    had 3.2M shares sold short in the 15 Jan 2025 report, 1.6× the same report last year.

    Same report last year: 2.0M; its normal report is 1.8M.

    See the evidence
    This period
    3.2M (the 15 Jan 2025 report)
    Normal report (median of 24 earlier)
    1.8M
    Typical spread (median absolute deviation)
    219K
    How far from its usual level
    +4.1
    Same report last year
    2.0M
    History used
    1,356 days
    2024-01-12: 2.0M2024-01-31: 2.2M2024-02-15: 2.0M2024-02-29: 1.8M2024-03-15: 1.9M2024-03-28: 1.6M2024-04-15: 1.6M2024-04-30: 1.6M2024-05-15: 1.6M2024-05-31: 1.6M2024-06-14: 1.6M2024-06-28: 1.8M2024-07-15: 2.0M2024-07-31: 1.9M2024-08-15: 1.8M2024-08-30: 1.9M2024-09-13: 2.3M2024-09-30: 2.5M2024-10-15: 2.2M2024-10-31: 1.8M2024-11-15: 1.2M2024-11-29: 1.5M2024-12-13: 2.1M2024-12-31: 2.2M2025-01-15: 3.2M
    the 15 Jan 2025 report24 earlier reportsnormal: 1.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 10 Dec 2024Filings record

    Director or officer change

  27. 28 May 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  28. 28 May 2024Filings record

    Director or officer change

  29. 9 Jan 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 9 Jan 2024Filings record

    Director or officer change

  31. 13 Jul 2023Short interest and volume change

    had 4.3M shares sold short in the 30 Jun 2023 report, 41× the same report last year.

    Same report last year: 106K; its normal report is 625K.

    See the evidence
    This period
    4.3M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    625K
    Typical spread (median absolute deviation)
    583K
    How far from its usual level
    +4.2
    Same report last year
    106K
    History used
    791 days
    2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M2023-04-28: 2.2M2023-05-15: 2.1M2023-05-31: 2.0M2023-06-15: 2.2M2023-06-30: 4.3M
    the 30 Jun 2023 report24 earlier reportsnormal: 625K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 28 Jun 2023Short interest and volume change

    had 2.2M shares sold short in the 15 Jun 2023 report, 26× the same report last year.

    Same report last year: 84K; its normal report is 254K.

    See the evidence
    This period
    2.2M (the 15 Jun 2023 report)
    Normal report (median of 24 earlier)
    254K
    Typical spread (median absolute deviation)
    225K
    How far from its usual level
    +5.9
    Same report last year
    84K
    History used
    776 days
    2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M2023-04-28: 2.2M2023-05-15: 2.1M2023-05-31: 2.0M2023-06-15: 2.2M
    the 15 Jun 2023 report24 earlier reportsnormal: 254K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 10 Jun 2023Short interest and volume change

    had 2.0M shares sold short in the 31 May 2023 report, 13× the same report last year.

    Same report last year: 157K; its normal report is 181K.

    See the evidence
    This period
    2.0M (the 31 May 2023 report)
    Normal report (median of 24 earlier)
    181K
    Typical spread (median absolute deviation)
    139K
    How far from its usual level
    +9.0
    Same report last year
    157K
    History used
    761 days
    2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M2023-04-28: 2.2M2023-05-15: 2.1M2023-05-31: 2.0M
    the 31 May 2023 report24 earlier reportsnormal: 181K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 25 May 2023Short interest and volume change

    had 2.1M shares sold short in the 15 May 2023 report, 8.9× the same report last year.

    Same report last year: 231K; its normal report is 181K.

    See the evidence
    This period
    2.1M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    181K
    Typical spread (median absolute deviation)
    134K
    How far from its usual level
    +9.5
    Same report last year
    231K
    History used
    745 days
    2022-05-13: 231K2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M2023-04-28: 2.2M2023-05-15: 2.1M
    the 15 May 2023 report24 earlier reportsnormal: 181K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 10 May 2023Short interest and volume change

    had 2.2M shares sold short in the 28 Apr 2023 report, 17× the same report last year.

    Same report last year: 127K; its normal report is 162K.

    See the evidence
    This period
    2.2M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    162K
    Typical spread (median absolute deviation)
    113K
    How far from its usual level
    +12.1
    Same report last year
    127K
    History used
    728 days
    2022-04-29: 127K2022-05-13: 231K2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M2023-04-28: 2.2M
    the 28 Apr 2023 report24 earlier reportsnormal: 162K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 26 Apr 2023Short interest and volume change

    had 2.1M shares sold short in the 14 Apr 2023 report, 13× the same report last year.

    Same report last year: 162K; its normal report is 159K.

    See the evidence
    This period
    2.1M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    159K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +13.4
    Same report last year
    162K
    History used
    714 days
    2022-04-14: 162K2022-04-29: 127K2022-05-13: 231K2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M2023-04-14: 2.1M
    the 14 Apr 2023 report24 earlier reportsnormal: 159K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 24 Apr 2023Filings record

    Director or officer change

  38. 13 Apr 2023Short interest and volume change

    had 2.0M shares sold short in the 31 Mar 2023 report, 2.7× the same report last year.

    Same report last year: 748K; its normal report is 159K.

    See the evidence
    This period
    2.0M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    159K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +12.8
    Same report last year
    748K
    History used
    700 days
    2022-03-31: 748K2022-04-14: 162K2022-04-29: 127K2022-05-13: 231K2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M2023-03-31: 2.0M
    the 31 Mar 2023 report24 earlier reportsnormal: 159K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 25 Mar 2023Short interest and volume change

    had 2.1M shares sold short in the 15 Mar 2023 report, 2.8× the same report last year.

    Same report last year: 754K; its normal report is 159K.

    See the evidence
    This period
    2.1M (the 15 Mar 2023 report)
    Normal report (median of 24 earlier)
    159K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +13.7
    Same report last year
    754K
    History used
    684 days
    2022-03-15: 754K2022-03-31: 748K2022-04-14: 162K2022-04-29: 127K2022-05-13: 231K2022-05-31: 157K2022-06-15: 84K2022-06-30: 106K2022-07-15: 73K2022-07-29: 47K2022-08-15: 37K2022-08-31: 21K2022-09-15: 52K2022-09-30: 193K2022-10-14: 168K2022-10-31: 131K2022-11-15: 109K2022-11-30: 148K2022-12-15: 314K2022-12-30: 935K2023-01-13: 1.0M2023-01-31: 1.9M2023-02-15: 2.2M2023-02-28: 1.8M2023-03-15: 2.1M
    the 15 Mar 2023 report24 earlier reportsnormal: 159K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 11 Mar 2023Insiders record

    Schuetz Thomas J. (CHIEF EXECUTIVE OFFICER) bought 10,000 shares of CMPX ($33,700) (dated 10 Mar 2023)

Showing the newest 40 of 106 entries; narrow the window or the kind of data to see older ones.

Not listed: 77 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001738021
Ticker
CMPX
Domain
compasstherapeutics.com
Employer name
compass therapeutics advisors, Compass Therapeutics, LLC (2 unverified)
Hq location
MA|BOSTON|02135 (1 unverified)
Name
Compass Therapeutics, Inc., Olivia Ventures, Inc.
  • DOL H-1B labor condition applications and PERM certifications12 data points6 Apr 2020 to 6 Jul 2026
  • SEC Form 13F institutional holdings180 data points31 Dec 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)100 records14 Aug 2018 to 20 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)445 data points31 Mar 2018 to 5 Nov 2026
  • SEC Form 4 insider transactions46 records, 132 data points23 Jun 2020 to 18 Nov 2026
  • FINRA short interest (twice monthly)377 data points30 Apr 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2538 data points2 Nov 2021 to 20 Nov 2026